Asklepios BioPharmaceutical (AskBio)

Research Triangle, NC · San Sebastian, ES
Hybrid — also manufactures internal programs
AAV
9 confirmed programs · 3 sponsors · Last scored 2026-04-02
59.7
Signal Score
○ FDA Inspections ✓ Clinical Trials (9) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Asklepios BioPharmaceutical (AskBio)

Signal Score
59.7/100 (as of 2026-04-02)
Quality Compliance
Assessment pending
Headquarters
Research Triangle, NC · San Sebastian, ES
Modalities
AAV
Active Programs
9 confirmed from ClinicalTrials.gov across 3 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 54.4
9 active programs across 3 sponsors
Modalities: AAV
4 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
9 active programs across 3 sponsors · Modalities: AAV · 4 programs in advanced phases (Phase 2/3)
Programs 9
Sponsors3
ModalitiesAAV
9 active programs across 3 sponsors
Modalities: AAV
4 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07282847 A Study to Evaluate Safety, Tolerability, and Efficacy of... PHASE1/PHASE2 Recruiting
NCT07081841 AB-1005 Long-Term Follow-up Study NA Enrolling By Invitation
NCT06285643 A Study of AAV2-GDNF in Adults With Moderate Parkinson's... PHASE2 Recruiting
NCT05598333 Phosphatase Inhibition by Intracoronary Gene Therapy in... PHASE2 Active Not Recruiting
NCT05230459 A Study to Evaluate the Safety of AB-1003 (Previously... PHASE1/PHASE2 Recruiting
NCT05699460 Pre-Gene Therapy Study in Parkinson's Disease and Multiple... NA Active Not Recruiting
NCT04167540 GDNF Gene Therapy for Parkinson's Disease PHASE1 Active Not Recruiting
NCT03533673 AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease PHASE1 Active Not Recruiting
NCT00428935 Safety Study of Mini-dystrophin Gene to Treat Duchenne... PHASE1 Completed
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability 68.0
Parent company: Bayer
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Bayer
Financial assessment: 68.0/100
Capacity 58.0
2 manufacturing sites
Sites: Research Triangle, NC, San Sebastian, ES
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
2 manufacturing sites
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Pharmaron Biologics
San Diego, CA · Shaoxing, CN
Signal Score: 85.6
AAV, Lentiviral, Plasmid
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 83.5
AAV, Plasmid DNA
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 83.5
AAV, mRNA/LNP, Biologics